CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Saxagliptin + metformin

Saxagliptin + metformin

Last Updated: June 6, 2013

Result type: Reports

Project Number: SR0336-000

Product Line: Reimbursement Review

Generic Name: Saxagliptin + metformin

Brand Name: Komboglyze

Manufacturer: Bristol-Myers Squibb / AstraZeneca Canada Inc.

Therapeutic Area: Diabetes Mellitus, Type 2

Indications: Diabetes Mellitus, Type 2

Submission Type: Initial

Project Status: Withdrawn

Saxagliptin + metformin

Files